Ambrisentan

Overview

Ambrisentan is an endothelin receptor antagonist used to treat pulmonary arterial hypertension, improving exercise ability and delaying clinical worsening. It works by selectively blocking the endothelin type-A receptors, leading to vasodilation.

API suppliers (3)

Suppliers of Ambrisentan backed by a verifiable FDA Type II Drug Master File. Source: FDA quarterly DMF list.

• Cipla USA, Inc.USA1 active DMF
• MATRIX PHARMACORP PRIVATE LTD1 active DMF
• WATSON PHARMA PRIVATE LTD

Patent & exclusivity (US)

Per the FDA Orange Book (17 approved US products), the latest listed US patent on Ambrisentan expires 13 Oct 2031. Generic API sourcing typically opens up once these lapse.

Therapeutic areas